PMID- 37928530
OWN - NLM
STAT- MEDLINE
DCOM- 20231114
LR  - 20231114
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of 
      immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre 
      real-world analysis with propensity score matching.
PG  - 1254158
LID - 10.3389/fimmu.2023.1254158 [doi]
LID - 1254158
AB  - BACKGROUND: This study aimed to evaluate the efficacy and safety of sequential 
      immune checkpoint inhibitors (ICIs) plus bevacizumab therapy after radiotherapy 
      for portal vein tumour thrombosis (PVTT) in patients with hepatocellular 
      carcinoma (HCC). METHODS: Retrospective data were collected from 113 patients 
      with HCC with PVTT. Patients in the PVTT radiotherapy (radiotherapy + ICIs + 
      bevacizumab) and control groups (ICIs + bevacizumab) were enrolled according to 
      propensity score matching (PSM) analysis (1:1). The differences in 
      progression-free survival (PFS), objective response rate (ORR), disease control 
      rate (DCR), and potential factors affecting PFS between the groups were analysed. 
      The adverse events (AEs) were compared between the two groups. RESULTS: There 
      were 47 patients in the two groups after PSM (1:1). The differences in neutrophil 
      and lymphocyte counts, neutrophil-to-lymphocyte ratio (NLR), CRP, and CD4, CD8, 
      and CD4-to-CD8 ratio before and after radiotherapy for PVTT (P < 0.05) in the 
      PVTT radiotherapy group were significant. The patients in the PVTT radiotherapy 
      group had a longer PFS (median, 9.6 vs. 5.4 months, P < 0.001), and the PFS rates 
      of 3, 6, 9, and 12 months were 97.87% vs. 94.19%, 80.85% vs. 44.68%, 53.19% vs. 
      6.38%, and 23.40% vs. 0.00%, respectively (P < 0.001). There were also 
      significant differences in the ORR (48.94% vs. 27.66%, P = 0.0339) and DCR 
      (97.87% vs. 82.98%, P = 0.0141) between the two groups, and no serious AEs were 
      observed. Multivariate Cox analysis showed that AFP expression, gross 
      classification of HCC, PVTT type, extrahepatic metastasis, PVTT radiotherapy, and 
      reduction in PVTT were independent factors influencing PFS (P < 0.05). 
      CONCLUSIONS: Sequential ICIs plus bevacizumab therapy after radiotherapy for PVTT 
      in patients with HCC is safe and feasible and may further prolong the PFS of 
      patients.
CI  - Copyright (c) 2023 Tang, He, Feng, Liao, Peng and Gao.
FAU - Tang, Cuiping
AU  - Tang C
AD  - Department of Gastroenterology and Hepatology, Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
AD  - Department of Graduate, The Second Clinical College of Chongqing Medical 
      University, Chongqing, China.
FAU - He, Qin
AU  - He Q
AD  - Department of Gastroenterology and Hepatology, The First People's Hospital of 
      Mianyang (SiChuan Mianyang 404 Hospital), Sichuan, China.
FAU - Feng, Jian
AU  - Feng J
AD  - Department of Oncology, Bishan Hospital of Chongqing Medical University, 
      Chongqing, China.
FAU - Liao, Ziyue
AU  - Liao Z
AD  - Department of Gastroenterology and Hepatology, Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
FAU - Peng, Yunli
AU  - Peng Y
AD  - Department of Gastroenterology and Hepatology, Bishan Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Gao, Jian
AU  - Gao J
AD  - Department of Gastroenterology and Hepatology, Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20231019
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Humans
MH  - Bevacizumab/therapeutic use
MH  - *Carcinoma, Hepatocellular/pathology/therapy
MH  - Immunotherapy
MH  - *Liver Neoplasms/pathology/therapy
MH  - Portal Vein/pathology
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - *Venous Thrombosis/radiotherapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10620737
OTO - NOTNLM
OT  - bevacizumab
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
OT  - portal vein tumour thrombosis
OT  - radiotherapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/06 06:43
MHDA- 2023/11/07 06:45
PMCR- 2023/01/01
CRDT- 2023/11/06 04:36
PHST- 2023/07/06 00:00 [received]
PHST- 2023/10/06 00:00 [accepted]
PHST- 2023/11/07 06:45 [medline]
PHST- 2023/11/06 06:43 [pubmed]
PHST- 2023/11/06 04:36 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1254158 [doi]
PST - epublish
SO  - Front Immunol. 2023 Oct 19;14:1254158. doi: 10.3389/fimmu.2023.1254158. 
      eCollection 2023.